Diabetes Mellitus: Pathophysiology, Vascular Damage, and Pharmacologic Management

Pathophysiology & Natural History of Diabetes Mellitus

  • Age-related trend: prevalence and risk rise with advancing age.
  • Progressive insulin resistance
    • Insulin less able to “unlock” GLUT channels → impaired cellular glucose uptake.
    • Results in persistent hyperglycemia.
  • Hyperglycemia-induced endothelial injury
    • Elevated glucose chemically damages endothelial lining (tunica intima) of all arteries.
    • Accelerates arteriosclerosis/atherosclerotic plaque formation → earlier & faster vessel stenosis.
    • Often clinically silent until perfusion demand exceeds narrowed lumen capacity.
  • Macrovascular consequences
    • Hypertension, peripheral artery disease (PAD).
    • Coronary artery disease → myocardial infarction (often silent).
    • Cerebrovascular disease → ischemic stroke/TIA.
  • Microvascular consequences
    • Retinopathy → peripheral vision loss / blindness.
    • Nephropathy → chronic kidney disease → renal failure.
    • Peripheral neuropathy → paresthesia, foot ulcers, gangrene → amputations.
    • Autonomic neuropathy
    • Genitourinary, GI, sexual, cardiovascular dysfunction (arrhythmias, silent MI).

Target Glycemic Control (Testing & Clinical Goals)

  • Fasting plasma glucose: 90\text{–}130\;\text{mg·dL}^{-1}.
  • Peak post-prandial glucose: < 180\;\text{mg·dL}^{-1}.
  • Hemoglobin A1cA_{1c} (3-month average): < 7\%.
  • Clinical pearl: Majority of patients require combination pharmacotherapy to reach targets.

Four Classic Oral Drug Categories ("Know for Exam")

  1. Secretagogues
    • Sulfonylureas
    • Meglitinides ("meglithymes")
  2. Biguanides (metformin)
  3. Thiazolidinediones (TZDs)
  4. α\alpha-Glucosidase inhibitors

Biguanides ▸ Metformin

  • First-line oral agent; nearly universal in T2DM.
  • Mechanisms
    • ↓ Hepatic gluconeogenesis.
    • ↑ GLP-1 secretion → early satiety.
    • ↑ Peripheral glucose uptake (muscle, adipose).
  • Major adverse event: lactic acidosis.
    • Risk amplified by dehydration, renal impairment, hepatic failure, radiocontrast iodine, large surgery w/ fluid shifts, unstable CHF, alcoholism.
  • Peri-operative implication: Hold pre-op & ensure hydration (e.g., contrast cystoscopy).

Sulfonylureas

  • Oldest class (since 1950s).
  • Require residual pancreatic β-cell function.
  • Effects
    • ↑ Insulin secretion → ↓ plasma glucose.
    • ↓ Micro & macrovascular complications by glycemic control.
  • Caveat
    • Persistent/severe hypoglycemia; stop when patient is NPO.

Meglitinides (Non-sulfa Secretagogues)

  • Similar to sulfonylureas but non-sulfonamide structure.
  • Short half-life → taken multiple times daily with meals.
  • Require β-cells; risk of hypoglycemia present.

Thiazolidinediones (TZDs)

  • Improve insulin sensitivity of liver, muscle, adipose.
  • Also ↓ hepatic glucose output.
  • Safety
    • Linked to cardiac events, liver failure, ↑ bone fracture risk.
    • 2010–2013: FDA black-box / restricted use; now reinstated w/ close monitoring.

α\alpha-Glucosidase Inhibitors (Acarbose, Miglitol)

  • Block intestinal enzymes that hydrolyze starch → monosaccharides.
  • Result: Slow & lower post-prandial glucose rise; carbohydrate passes through unabsorbed.
  • Essentially "dietary carb absorber blockers".

GLP-1 Receptor Agonists (Incretin Mimetics)

  • Examples: Ozempic, Mounjaro, exenatide, liraglutide, dulaglutide, semaglutide, etc.
  • Mechanisms
    • Potentiate glucose-dependent insulin release.
    • ↓ Serum glucagon (inhibit α-cell).
    • Markedly slow gastric emptying → early & prolonged satiety.
  • Clinical effects/benefits
    • Weight loss, no intrinsic hypoglycemia.
    • ↓ Major adverse cardiovascular events; cardioprotective (↑ cardiac output).
    • Nephroprotective, neuroprotective (↓ neural apoptosis; ↑ neurogenesis).
    • Anti-inflammatory; immune support.
  • Adverse effects
    • GI: nausea, vomiting, diarrhea.
    • Pancreatitis; rare medullary thyroid carcinoma.
  • ASA peri-operative guidance
    • Daily dosing: hold morning of surgery.
    • Weekly dosing: hold for 1 week pre-op.
    • Consider gastric ultrasound if uncertain gastric contents (delayed emptying).

DPP-4 Inhibitors ("Gliptins")

  • Inhibit dipeptidyl peptidase-4 enzyme that degrades GLP-1 & GIP.
  • Resultant ↑ incretin levels →
    • ↑ β-cell insulin secretion (fasting & post-prandial).
    • ↓ Glucagon.
    • ↓ Gastric emptying, ↑ satiety.
  • Additional properties
    • Antihypertensive, anti-inflammatory.
    • Anti-apoptotic → neuroprotective.
    • Immunomodulatory benefits on heart, kidney, vasculature.
  • Complementary use with GLP-1 agonists (direct + indirect incretin boost).

Integrated Clinical & Ethical Implications

  • Silent vascular damage highlights need for routine screening (ethical duty to educate & monitor).
  • Poly-drug therapy demands medication reconciliation to avoid additive hypoglycemia, lactic acidosis, or peri-operative aspiration.
  • Weight-loss marketing of GLP-1 agents vs. limited supply for diabetics → equity & allocation issues.

Quick Numerical & Formula Recap

  • Glycemic goals: Fasting 90!–!130\text{Fasting } 90!\text{–}!130, \text{PP} < 180, A_{1c} < 7\%.
  • Lactic acidosis conceptual: Lactate<em>↑+Metformin⇒pH</em>↓\text{Lactate}<em>{\text{↑}} + \text{Metformin} \Rightarrow \text{pH}</em>{\text{↓}} (risk amplified by renal ↓ clearance).

Examination Hot-Spots

  • Metformin: mechanism + lactic acidosis risk factors + contrast/surgery hold.
  • GLP-1 agonists: slow gastric emptying → aspiration risk & ASA hold timelines.
  • Distinguish direct incretin agonists (GLP-1) vs. indirect (DPP-4 inhibitors).
  • Which classes cause hypoglycemia (secretagogues) vs. which do not (metformin, GLP-1, α\alpha-GI blockers, TZDs unless combined).
  • β-cell dependence: sulfonylureas & meglitinides require some β-cell function.
  • Contra-indications/black-box histories (TZDs → cardiac).